Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Front Immunol. 2024 Feb 26;15:1293931. doi: 10.3389/fimmu.2024.1293931. eCollection 2024.
Front Immunol. 2024.
PMID: 38469299
Free PMC article.
Clinical Trial.
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, García-Domínguez DJ, Hontecillas-Prieto L, Espejo-García P, Fernández-Román I, Provencio-Pulla M, Sánchez-Beato M, Navarro M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Sánchez-Margalet V, Rueda-Domínguez A, de la Cruz-Merino L.
Palazón-Carrión N, et al. Among authors: salar silvestre a.
Clin Cancer Res. 2022 Sep 1;28(17):3658-3668. doi: 10.1158/1078-0432.CCR-22-0588.
Clin Cancer Res. 2022.
PMID: 35727601
Free PMC article.
Clinical Trial.
Item in Clipboard
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Dominguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodriguez-Abreu D, Galvez-Carvajal L, Provencio M, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA).
Jiménez-Cortegana C, et al. Among authors: salar silvestre a.
J Immunother Cancer. 2021 Jun;9(6):e002323. doi: 10.1136/jitc-2020-002323.
J Immunother Cancer. 2021.
PMID: 34158317
Free PMC article.
Item in Clipboard
Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.
Jolis L, Carabantes F, Pernas S, Cantos B, López A, Torres P, Funes C, Caballero D, Benedit P, Salar A; PRAXIS Study Group.
Jolis L, et al.
Eur J Cancer Care (Engl). 2013 Jul;22(4):513-21. doi: 10.1111/ecc.12057. Epub 2013 Jun 3.
Eur J Cancer Care (Engl). 2013.
PMID: 23730920
Item in Clipboard
Cite
Cite